



NACUITY
PHARMACEUTICALS, INC

ADVANCING A PROMISING TREATMENT FOR RETINITIS PIGMENTOSA AND OTHER OCULAR DISEASES



LEADERSHIP TEAM




Halden Conner
Chairman, CEO, Co-Founder

- Former Alcon Laboratories Board Member
- Former Wilmer Advisory Council Member
- Co-founder, Protom International



G. Michael Wall, PhD
SVP, CSO

- 22 years at Alcon Laboratories, directing all phases of ophthalmic, otic, nasal drug development, numerous products
- 39 patents, >100 pubs, 2 books, 3 chapters
- Directed more than 40 clinical trials
- PhD, Med Chem, Univ Miss Sch Pharm
- Harvard Business School AMP



Lee Anderson, MD
Ophthalmologist in Residence

- Over 20 years in practice specializing in Ophthalmology and Retinal Disease
- MD, University of Texas Medical Branch
- Fellowship, Bascom Palmer Eye Institute



Charles Lieser, JD, CPA
CFO

- Owner, Weaver, LLP, 32 yrs
- 40 plus years experience public accounting
- Principal and advisor to numerous companies



Jami R. Kern, MBA, PhD
VP, Clinical Affairs

- Extensive experience, pharmaceutical and medical device industries
- Led clinical development and medical affairs at Alcon Research for 15 years
- MBA, Neeley School of Business at Texas Christian University
- PhD in Biomedical Science, Molecular Biology & Biochemistry, University of North Texas Health Science Center

SCIENTIFIC ADVISORY BOARD



David Birch, PhD

- Scientific Director, Retina Foundation of the Southwest
- Director, Rose-Silverthorne Retinal Degenerations Laboratory
- PhD, University of California, Santa Barbara



Jacque Duncan, M.D.

- Professor, Clinical Ophthalmology and Academic Director, Retina Service, Department of Ophthalmology, University of California San Francisco
- Chair, Foundation Fighting Blindness Scientific Advisory Board
- M.D., University of California San Francisco



Nancy Holekamp, MD

- Professor of Clinical Ophthalmology and Visual Sciences, Washington University School of Medicine
- Director of Retina Services, Pepose Vision Institute
- MD, Johns Hopkins University School of Medicine



Mark Pennesi, MD, PhD

- Associate Prof and Chief of Ophthalmic Genetics, Casey Eye Institute
- Prevent Blindness and FFB development awards for transitional research in RP
- MD/PhD, Baylor College of Medicine



Tim Stout, MD, PhD, MBA

- Director, Cullen Eye Institute, Baylor College of Medicine
- Chair, Department of Ophthalmology, Baylor College of Medicine
- MD/PhD, Baylor College of Medicine
- MBA, University of Oregon

RETINITIS PIGMENTOSA (RP)

ORAL NPI-001 (NACA)



SAFETY AND EFFICACY OF NPI-001 TABLETS FOR RP ASSOCIATED WITH USHER SYNDROME (SLO RP)

WHAT


Phase 1/2 safety & efficacy clinical study C-18-04

- Initiated January 2020
- 48 USH subjects, randomized 2 (active):1 (placebo)
- 24-month study
- Target population has some rod loss, but mostly viable cones
- Key Efficacy Endpoints:
 - Pointwise retinal sensitivity (MAIA microperimetry)
 - EZ Area (SD-OCT)
 - Best Corrected Visual Acuity (eVA)

WHY

Designed to generate data that can be used to:

- Support the safety of a dosage up to 500mg/day
- Provide clinical proof of concept for treatment of RP associated with USH
- Design a confirmatory clinical study for the treatment of RP
- Support breakthrough application (TGA, FDA)



PRELIMINARY RESULTS FROM USH STUDY EXPECTED IN 2021

